Multiple Sclerosis Therapeutics Market will grow at 2.5% CAGR: Impact of COVID-19 on Demand and Supply of Multiple Sclerosis Therapeutics

“The Multiple Sclerosis Therapeutics Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.”

The Multiple Sclerosis Therapeutics research report covers the current scenario and the growth prospects of the global Multiple Sclerosis Therapeutics industry forecast 2021 – 2027. The report enlists several important factors, starting from the basics principal to advanced market intelligence which play a vital part in strategizing. Multiple Sclerosis Therapeutics manufacturers and is a important source of guidance and direction for companies and individuals interested in the Multiple Sclerosis Therapeutics industry.

Get PDF Here 

Multiple sclerosis (MS) is a demyelinating disease in which neurons in the brain lose their insulating coverings. The condition causes the neurological system to malfunction, resulting in a variety of indications and symptoms including cognitive, physical, and psychological issues. SPMS (secondary progressive MS), RRMS (Relapsing-remitting MS), and PPMS (primary progressive MS) are the three forms of MS. The most frequent kind of relapsed-remitting MS is RPMS, which is marked by distinct episodes with growing neurological symptoms, PPMS is a rare form characterized by slow disease progression, and SPMS is usually found in patients with relapsed-remitting MS. Partial or full vision loss, persistent visual loss, poor coordination, and slurred speech are the most frequent signs of the illness.

The emergence of the disease is caused by a mix of genetic and environmental factors. MS is two to three times more prevalent among women than in males, according to a 2013 research by the International Progressive Alliance, implying that hormones have a vital role in ensuring vulnerability to the illness.

In 2016, the global multiple sclerosis therapeutics market was estimated at US$ 19.6 billion, with a CAGR of 2.5 percent projected during the forecast period (2017 – 2025).

Drivers

Multiple sclerosis is becoming more common, which is expected to boost the global multiple sclerosis therapeutics market growth. Multiple sclerosis is a debilitating neurological disease that primarily affects adults between the ages of 20 and 50. According to the Multiple Sclerosis Foundation, this autoimmune disease affects 2.5 million individuals worldwide, with an annual incidence of about 7 cases per 100,000. According to the study, incidence rates vary by ethnicity and geographical latitude, ranging from 50 to 120 individuals per 100,000. Due to the high incidence of the disease and the growing economic impact of the disease, North America dominates the market for multiple sclerosis treatments. This has led to the introduction of innovative therapies.

Organizations employ intensive R&D projects in order to boost market expansion. Numerous organizations such as the National Institute of Neurological Disorders and Stroke, the National MS Society, and the Parkinson’s Action Network, are working hard to develop new medicines for MS, which is a major driver driving the global multiple sclerosis therapeutics market. The Progressive MS Alliance was founded in 2013 to particularly research and develop more therapy opportunities for consumers with progressive forms of MS. There are currently 20 projects underway with researchers from nine countries. In addition, the MS Society of Canada and the Canadian Institute of Health Research funded a new study at the University of Alberta in 2015 to look into novel therapeutic strategies for reducing inflammation in the brain, which is a major element in the muscular disability associated with multiple sclerosis.

Restraints

Multiple sclerosis comes second after cardiac arrest in terms of direct and indirect health care expenditures, with direct and indirect costs ranging from US$ 8,528 to US$ 54,244 per patient per year, according to a 2015 study by Healthline Media. The global multiple sclerosis therapeutics market for multiple sclerosis medicines is being held back by increasing therapy costs.

Competitive Landscape

Key companies contributing in the global multiple sclerosis therapeutics market are Sanofi S.A., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, AbbVie, Inc., Merck & Co., Inc., Biogen Idec, and Bayer AG.

“Limited Time Offer”

Get This premium report with Instant US$ 2000 discount @  https://www.coherentmarketinsights.com/promo/buynow/1310

Main points in Multiple Sclerosis Therapeutics Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Multiple Sclerosis Therapeutics Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Multiple Sclerosis Therapeutics Industry Impact

Chapter 2 Global Multiple Sclerosis Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Multiple Sclerosis Therapeutics (Volume and Value) by Type
2.3 Global Multiple Sclerosis Therapeutics (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Multiple Sclerosis Therapeutics Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Multiple Sclerosis Therapeutics Market Analysis
Chapter 6 East Asia Multiple Sclerosis Therapeutics Market Analysis
Chapter 7 Europe Multiple Sclerosis Therapeutics Market Analysis
Chapter 8 South Asia Multiple Sclerosis Therapeutics Market Analysis
Chapter 9 Southeast Asia Multiple Sclerosis Therapeutics Market Analysis
Chapter 10 Middle East Multiple Sclerosis Therapeutics Market Analysis
Chapter 11 Africa Multiple Sclerosis Therapeutics Market Analysis
Chapter 12 Oceania Multiple Sclerosis Therapeutics Market Analysis
Chapter 13 South America Multiple Sclerosis Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Multiple Sclerosis Therapeutics Business
Chapter 15 Global Multiple Sclerosis Therapeutics Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology

Continued……

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com